Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: RAPAMUNE

Summary for Tradename: RAPAMUNE

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: RAPAMUNE

Clinical Trials for: RAPAMUNE

Prospective Study of Rapamycin for the Treatment of SLE
Status: Recruiting Condition: Systemic Lupus Erythematosus (SLE)

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Status: Recruiting Condition: Advanced Cancer

Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Status: Active, not recruiting Condition: Glioma

Comparing Everolimus and Sirolimus in Renal Transplant Recipients
Status: Recruiting Condition: Renal Failure

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Active, not recruiting Condition: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Status: Recruiting Condition: Advanced Cancer; Solid Tumor

Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma
Status: Not yet recruiting Condition: Recurrent Childhood Ependymoma

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Status: Active, not recruiting Condition: Waldenstrom's Macroglobulinemia

Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
Status: Recruiting Condition: Kidney Transplantation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
SOLUTION;ORAL021083Sep 15, 1999RXYes5,100,899*PED<disabled>Y<disabled>
Pf Prism Cv
SOLUTION;ORAL021083Sep 15, 1999RXYes5,536,729*PED<disabled>Y<disabled>
Pf Prism Cv
TABLET;ORAL021110Aug 22, 2002RXYes5,100,899*PED<disabled>Y<disabled>
Pf Prism Cv
TABLET;ORAL021110Aug 22, 2002RXYes5,989,591*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RAPAMUNE

Drugname Dosage Strength RLD Submissiondate
sirolimusTablets0.5 mgRapamune8/25/2010
sirolimusTablets1 mg and 2 mgRapamune12/17/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology